Spotlight On... North Carolina may lose pharma project after passing law targeting LGBT community; Lilly plots €35M plant in Ireland; Baxter among potential bidders for India's Gland Pharma; and more...

Two weeks ago North Carolina governor Gov. Pat McCrory was pointing to a proposed project by New Jersey-based Braeburn Pharmaceuticals and bragging about what a great job the state has done attracting pharma companies. But Braeburn is having second thoughts about the state after the governor last week signed a bill that eliminated local protections for gay and transgender people and limits the bathroom choices they have. In a statement to WNCN in Durham, NC, Braeburn called the law "unjust. It is slated to receive up to $275,000 in incentives for the project. "Braeburn Pharmaceuticals believes in fair treatment and equality for all individuals in their communities. We oppose any legislation that discriminates against the LGBT community," the company said. More from FiercePharmaManufacturing

@FiercePharma: Allergy battle goes young as GSK's Flonase, Sanofi's Nasacort roll out kid-labeled OTC sprays. FiercePharmaMarketing story | Follow @FiercePharma

@CarlyHFierce: Drugmakers see no marketing leverage from FDA biosim guidelines. More from FiercePharmaMarketing | Follow @CarlyHFierce

> Eli Lilly ($LLY) plans to spend €35 million on a new high-tech production plant in Kinsale, Ireland. Report

> U.S.-based Baxter ($BAX) and India's Torrent Pharmaceuticals are said to be eyeing the buyout of another Indian company, Gland Pharma. Report

> Prescriptions for statin meds, expected to skyrocket after the American Heart Association and American College of Cardiology recommended broader use, appear to have dropped since then instead. Report

Medical Device News

@FierceMedDev: Edwards up 13% on Sapien TAVR data in intermediate-risk heart patients. Report | Follow @FierceMedDev

> Plastic-softening chemicals in medical devices could lead to brain problems in kids: Scientists. Article

Biotech News

@FierceBiotech: Venter's Human Longevity firm raises $220M with help from Celgene, Illumina. Article | Follow @FierceBiotech

@JohnCFierce: Miss our story on being accused of misrepresenting its data on rociletinib? Report | Follow @JohnCFierce

> Intercept surges as FDA review hesitates on endorsing OCA data, but doesn't hate it. More

> As Allergan buyout hangs in balance, Motus reports progress on GI drug. Story

> Gilead gains next-gen HIV approval from FDA as it looks to beat back competition. Article

Pharma Manufacturing News

> Drug company may kill NC plant project over transgender issue. More

> PuraCap snags second new production site in a week. Report

> Gilead contractor PharmaChem starts $120M Bahamas expansion. Story

> Sun closing Ranbaxy plant in Ireland. Item

> Rusan plant in India remains under EU ban due to persistent GMP problems. Article

Drug Delivery News

> Nanoparticle 'cluster-bomb' penetrates tumors to reduce chemo doses. Report

> Celator raises $40M through common stock offering to support its liposomal cancer candidate. More

> India's Rusan Pharma opens transdermal patch plant in Gujarat. Story

> MIT team invents machine for making personalized drugs 'on demand.' Item

> Augmenix touts study of its rectal spacer to cut side effects of prostate cancer radiotherapy. Article

Pharma Asia News

> Alibaba Health drops China online pharmacy plans, blames complex regulatory environment. Report

> Samsung Bioepis aims at AbbVie Humira patents in U.K. lawsuit. Story

> Chugai, PharmaMar post positive blood cancer results for new sea squirt drug. Article

> Indian pharma to face U.S. headwinds, but growth to remain 'stable.' More

> Australia's biotech industry sings Korea's praises, asks for more tie-ups. Item

And Finally... Celgene ($CELG) is collaborating with Vanderbilt University to accelerate development of personalized therapies. Report

Suggested Articles

Merck CEO Ken Frazier and his colleagues vowed during the company's Investor Day that a healthy pipeline will drive margin expansion.

With the list of 34 drugs, the Chinese government is encouraging drugmakers to copy them under regulator's priority review pathway.

Despite a veritable graveyard of drug prospects in hard-to-treat glioblastoma, Bayer hopes underperforming Stivarga can crack the code in new trials.